Exocrine Pancreatic Insufficiency Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and diagnosis, growing prevalence of digestive disorders, aging population, and pancreatic function decline, rise in gastrointestinal surgeries.

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued increase in awareness and screening, expanding geriatric population, rising incidence of chronic diseases, improvements in patient access to healthcare, research and development in digestive health. Major trends in the forecast period include telehealth and digital health solutions, collaborative research initiatives, focus on pediatric epi, regulatory advances and fast-track designations, market expansion in emerging economies, advancements in healthcare infrastructure.

The increasing prevalence of chronic diseases is expected to drive the growth of the exocrine pancreatic insufficiency market in the future. Chronic diseases are long-term conditions that last for extended periods, typically over three months. The ongoing presence of these conditions can also heighten the risk of developing secondary complications, such as exocrine pancreatic insufficiency, which in turn promotes better management of chronic diseases through medical treatments and therapies, potentially extending the lives of affected individuals. For example, in September 2023, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% of these attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Consequently, the rise in chronic diseases will accelerate the growth of the exocrine pancreatic insufficiency market.

The escalating cases of diabetes are expected to fuel the growth of the exocrine pancreatic insufficiency market. Diabetes, a chronic health condition characterized by inadequate insulin production or utilization by the body, leads to an accumulation of excessive blood sugar in the bloodstream. Pancreatic enzyme replacement treatment (PERT) becomes essential to supply adequate digestive enzymes for exocrine pancreatic insufficiency (EPI) and maintain the body's insulin levels. For instance, a report from the Institute for Health Metrics and Evaluation in June 2023 projected global diabetes cases to reach 1.3 billion by 2050, up from 529 million in 2022. Therefore, the increasing prevalence of diabetes is expected to drive the growth of the exocrine pancreatic insufficiency market.

Leading companies in the exocrine pancreatic insufficiency market are focusing on establishing patient advocacy initiatives, such as offering comprehensive nutritional guidance and support. These efforts aim to raise awareness, educate, and improve the management of the condition for those affected. Comprehensive nutritional guidance is an all-encompassing approach that customizes dietary recommendations according to individual needs, health status, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For example, in June 2024, Nestlé Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. This platform provides personalized nutritional resources and expert advice for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and general wellness. Its goal is to empower users on their weight management journey by addressing specific dietary needs and building community support.

In December 2023, Codexis, a US-based pharmaceutical company, acquired a division of Nestlé Health Science for an undisclosed amount. Through this acquisition, Codexis aims to monetize its asset CDX-7108, concentrate on core projects, and leverage Nestlé's expertise to expedite development while maintaining economic interest. Nestlé Health Science, a Switzerland-based science-driven nutrition company, offers specialized nutritional products to aid individuals with exocrine pancreatic insufficiency by enhancing digestion and nutrient absorption.

Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics.

North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the insufficient production or release of digestive enzymes by the pancreas into the small intestine. These enzymes are crucial for the proper digestion and absorption of nutrients from ingested food. Exocrine pancreatic insufficiency can result in malnutrition and various digestive symptoms, such as diarrhea, abdominal pain, bloating, and weight loss.

The primary types of treatments for exocrine pancreatic insufficiency include nutritional management, pancreatic enzyme replacement therapy (PERT), and other interventions. Nutritional management involves planning and implementing dietary strategies to optimize an individual's nutritional status, supporting overall health and well-being. This approach is essential in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed through imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others. These diagnostic tests help identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, and weight loss. The drugs used for treating exocrine pancreatic insufficiency are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. These medications are utilized by end users such as hospitals, specialty clinics, and individuals receiving care at home.

The exocrine pancreatic insufficiency market research report is one of a series of new reports that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.